184 related articles for article (PubMed ID: 34008071)
21. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects.
Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M
Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
Lee HJ; Han E; Kim H
Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab biosimilar shows potential for breast cancer.
Baker H
Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154
[No Abstract] [Full Text] [Related]
24. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
[TBL] [Abstract][Full Text] [Related]
25. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
26. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
27. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
Hara F; Tajima K; Tanabe K
Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
[TBL] [Abstract][Full Text] [Related]
28. Biosimilars in oncology: everybody agrees but nobody uses?
Gyawali B
Recenti Prog Med; 2017 Apr; 108(4):172-174. PubMed ID: 28492585
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of biosimilar uptake in emerging markets.
Chhabra H; Mouslim MC; Kashiramka S; Rathore AS
Expert Opin Biol Ther; 2022 Jun; 22(6):679-688. PubMed ID: 35535988
[TBL] [Abstract][Full Text] [Related]
30. How can biosimilars change the trajectory of breast cancer therapy?
Trapani D; Curigliano G
Expert Rev Anticancer Ther; 2020 May; 20(5):325-328. PubMed ID: 32298188
[No Abstract] [Full Text] [Related]
31. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
[TBL] [Abstract][Full Text] [Related]
32. Key drivers for market penetration of biosimilars in Europe.
Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
[No Abstract] [Full Text] [Related]
33. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
34. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
35. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Tari DU; Troncone C; Fontana A; Ientile V; Gini R; Santoro D; Santarpia M; Genazzani A; Uomo I; Pastorello M; Addario WS; Scondotto S; Cananzi P; Caputi AP; Trifirò G
BioDrugs; 2015 Aug; 29(4):275-84. PubMed ID: 26169209
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
Barszczewska O; Piechota A
Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
[TBL] [Abstract][Full Text] [Related]
37. Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
Horn DM; Alpert AE; Duggan MG; Garcia NA; Jacobson M
JCO Oncol Pract; 2023 Apr; 19(4):e476-e483. PubMed ID: 36638330
[TBL] [Abstract][Full Text] [Related]
38. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China.
Wu Q; Lian Z; Wang X; Cheng H; Sun J; Yu H; Zhang G; Wu F; Liu J; Chen C
Front Pharmacol; 2022; 13():1044798. PubMed ID: 36712662
[No Abstract] [Full Text] [Related]
40. "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars.
Varma M; Almarsdóttir AB; Druedahl LC
Basic Clin Pharmacol Toxicol; 2022 May; 130(5):581-591. PubMed ID: 35261174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
